Analysis of estrogens in serum and plasma from postmenopausal women: Past present, and future

Steroids

Volumn 75, Issue 4-5, 2010, Pages 297-306

  Blair, Ian A ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Catechol estrogens; Electrochemiluminescence immunoassay; Estrogens; Gas chromatography mass spectrometry; Liquid chromatography mass spectrometry; Radioimmunoassay; Stable isotope dilution

Indexed keywords

2 METHOXY ESTRADIOL; ANTINEOPLASTIC AGENT; ESTRADIOL; ESTRADIOL DERIVATIVE; ESTROGEN; ESTRONE; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; BLOOD SAMPLING; BREAST CANCER; BREAST CARCINOGENESIS; CANCER RISK; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DRUG STRUCTURE; ESTROGEN BLOOD LEVEL; ESTROGEN METABOLISM; ESTROGEN SYNTHESIS; ESTRONE BLOOD LEVEL; FEMALE; GLIOMA; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HIGH RISK POPULATION; HUMAN; ISOTOPE LABELING; LIQUID CHROMATOGRAPHY; NONHUMAN; POSTMENOPAUSE; QUADRUPOLE MASS SPECTROMETRY; RADIOIMMUNOASSAY; REVIEW; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; SEX HORMONE DETERMINATION; TANDEM MASS SPECTROMETRY;

ESTRADIOL; ESTROGENS; ESTRONE; FEMALE; HUMANS; POSTMENOPAUSE;

EID: 77949263021     PISSN: 0039128X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.steroids.2010.01.012     Document Type: Review

References (123)

1. Liehr J.G. Is estradiol a genotoxic mutagenic carcinogen?. Endocr Rev 21 (2000) 40-54
2. Liehr J.G. Genotoxicity of the steroidal oestrogens oestrone and oestradiol: possible mechanism of uterine and mammary cancer development. Hum Reprod Update 7 (2001) 273-281
3. Falandry C., Canney P.A., Freyer G., and Dirix L.Y. Role of combination therapy with aromatase and cyclooxygenase-2 inhibitors in patients with metastatic breast cancer. Ann Oncol 20 (2009) 615-620
4. Santen R.J. Assessing individual risk for breast cancer: role of oestrogens and androgens. Breast Cancer Res 10 (2008) S10
5. ESHRE Capri Workshop Group. Hormones and breast cancer. Hum Reprod Update 10 (2004) 281-293
6. Santen R.J., Boyd N.F., Chlebowski R.T., Cummings S., Cuzick J., Dowsett M., et al. Critical assessment of new risk factors for breast cancer: considerations for development of an improved risk prediction model. Endocr Relat Cancer 14 (2007) 169-187
7. Chan K., and Morris G.J. Chemoprevention of breast cancer for women at high risk. Semin Oncol 33 (2006) 642-646
8. Tyrer J., Duffy S.W., and Cuzick J. A breast cancer prediction model incorporating familial and personal risk factors. Stat Med 23 (2004) 1111-1130
9. Dorgan J.F., Longcope C., Stephenson Jr. H.E., Falk R.T., Miller R., Franz C., et al. Relation of prediagnostic serum estrogen and androgen levels to breast cancer risk. Cancer Epidemiol Biomarkers Prevent 5 (1996) 533-539
10. Lamar C.A., Dorgan J.F., Longcope C., Stanczyk F.Z., Falk R.T., and Stephenson Jr. H.E. Serum sex hormones and breast cancer risk factors in postmenopausal women. Cancer Epidemiol Biomarkers Prevent 12 (2003) 380-383
11. Kaaks R., Rinaldi S., Key T.J., Berrino F., Peeters P.H., Biessy C., et al. Postmenopausal serum androgens, oestrogens and breast cancer risk: the European prospective investigation into cancer and nutrition. Endocr Relat Cancer 12 (2005) 1071-1082
12. Eliassen A.H., Missmer S.A., Tworoger S.S., and Hankinson S.E. Circulating 2-hydroxy- and 16alpha-hydroxy estrone levels and risk of breast cancer among postmenopausal women. Cancer Epidemiol Biomarkers Prevent 17 (2008) 2029-2035
13. Arslan A.A., Shore R.E., Afanasyeva Y., Koenig K.L., Toniolo P., and Zeleniuch-Jacquotte A. Circulating estrogen metabolites and risk for breast cancer in premenopausal women. Cancer Epidemiol Biomarkers Prevent 18 (2009) 2273-2279
14. Dowsett M., and Folkerd E. Deficits in plasma oestradiol measurement in studies and management of breast cancer. Breast Cancer Res 7 (2005) 1-4
15. Stanczyk F.Z., Lee J.S., and Santen R.J. Standardization of steroid hormone assays: why, how, and when?. Cancer Epidemiol Biomarkers Prevent 16 (2007) 1713-1719
16. Boyd N., Martin L., Gunasekara A., Melnichouk O., Maudsley G., Peressotti C., et al. Mammographic density and breast cancer risk: evaluation of a novel method of measuring breast tissue volumes. Cancer Epidemiol Biomarkers Prevent 18 (2009) 1754-1762
17. Chen Z., Arendell L., Aickin M., Cauley J., Lewis C.E., and Chlebowski R. Hip bone density predicts breast cancer risk independently of Gail score: results from the Women's Health Initiative. Cancer 113 (2008) 907-915
18. Cleary M.P., and Grossmann M.E. Minireview: obesity and breast cancer: the estrogen connection. Endocrinology 150 (2009) 2537-2542
19. Gail M.H. Value of adding single-nucleotide polymorphism genotypes to a breast cancer risk model. J Natl Cancer Inst 101 (2009) 959-963
20. Santen R.J., Brodie H., Simpson E.R., Siiteri P.K., and Brodie A. History of aromatase: saga of an important biological mediator and therapeutic target. Endocr Rev 30 (2009) 343-375
21. Simpson E., Rubin G., Clyne C., Robertson K., O'Donnell L., Jones M., et al. The role of local estrogen biosynthesis in males and females. Trends Endocrinol Metab 11 (2000) 184-188
22. Thomas J.L., Duax W.L., Addlagatta A., Kacsoh B., Brandt S.E., and Norris W.B. Structure/function aspects of human 3beta-hydroxysteroid dehydrogenase. Mol Cell Endocrinol 215 (2004) 73-82
23. Adamski J., and Jakob F.J. A guide to 17beta-hydroxysteroid dehydrogenases. Mol Cell Endocrinol 171 (2001) 1-4
24. Andersson S. Molecular genetics of androgenic 17 beta-hydroxysteroid dehydrogenases. J Steroid Biochem Mol Biol 55 (1995) 533-534
25. Li Z., Luu-The V., Poisson-Pare D., Ouellet J., Li S., Labrie F., et al. Expression of enzymes involved in synthesis and metabolism of estradiol in human breast as studied by immunocytochemistry and in situ hybridization. Histol Histopathol 24 (2009) 273-282
26. Plourde M., Ferland A., Soucy P., Hamdi Y., Tranchant M., Durocher F., et al. Analysis of 17beta-hydroxysteroid dehydrogenase types 5, 7, and 12 genetic sequence variants in breast cancer cases from French Canadian Families with high risk of breast and ovarian cancer. J Steroid Biochem Mol Biol 116 (2009) 134-153
27. Penning T.M., Jin Y., Steckelbroeck S., Lanisnik R.T., and Lewis M. Structure-function of human 3 alpha-hydroxysteroid dehydrogenases: genes and proteins. Mol Cell Endocrinol 215 (2004) 63-72
28. Penning T.M., Burczynski M.E., Jez J.M., Hung C.F., Lin H.K., Ma H., et al. Human 3alpha-hydroxysteroid dehydrogenase isoforms (AKR1C1-AKR1C4) of the aldo-keto reductase superfamily: functional plasticity and tissue distribution reveals roles in the inactivation and formation of male and female sex hormones. Biochem J 351 (2000) 67-77
29. Song D., Liu G., Luu-The V., Zhao D., Wang L., Zhang H., et al. Expression of aromatase and 17beta-hydroxysteroid dehydrogenase types 1, 7 and 12 in breast cancer. An immunocytochemical study. J Steroid Biochem Mol Biol 101 (2006) 136-144
30. Miki Y., Suzuki T., Tazawa C., Yamaguchi Y., Kitada K., Honma S., et al. Aromatase localization in human breast cancer tissues: possible interactions between intratumoral stromal and parenchymal cells. Cancer Res 67 (2007) 3945-3954
31. Jansson A. 17Beta-hydroxysteroid dehydrogenase enzymes and breast cancer. J Steroid Biochem Mol Biol 114 (2009) 64-67
32. Breitling R., Krazeisen A., Moller G., and Adamski J. 17beta-hydroxysteroid dehydrogenase type 7-an ancient 3-ketosteroid reductase of cholesterogenesis. Mol Cell Endocrinol 171 (2001) 199-204
33. Wei C., Zhu P., Shah S.J., and Blair I.A. 15-Oxo-eicosatetraenoic acid, a metabolite of macrophage 15-hydroxyprostaglandin dehydrogenase that inhibits endothelial cell proliferation. Mol Pharm 76 (2009) 516-529
34. Vihko P., Isomaa V., and Ghosh D. Structure and function of 17beta-hydroxysteroid dehydrogenase type 1 and type 2. Mol Cell Endocrinol 171 (2001) 71-76
35. Lukacik P., Keller B., Bunkoczi G., Kavanagh K.L., Lee W.H., Adamski J., et al. Structural and biochemical characterization of human orphan DHRS10 reveals a novel cytosolic enzyme with steroid dehydrogenase activity. Biochem J 402 (2007) 419-427
36. Sasano H., Suzuki T., Miki Y., and Moriya T. Intracrinology of estrogens and androgens in breast carcinoma. J Steroid Biochem Mol Biol 108 (2008) 181-185
37. LaFleur J., McAdam-Marx C., Kirkness C., and Brixner D.I. Clinical risk factors for fracture in postmenopausal osteoporotic women: a review of the recent literature. Ann Pharmacother 42 (2008) 375-386
38. Key T., Appleby P., Barnes I., and Reeves G. Endogenous sex hormones and breast cancer in postmenopausal women: reanalysis of nine prospective studies. J Natl Cancer Inst 94 (2002) 606-616
39. Pischon T., Nothlings U., and Boeing H. Obesity and cancer. Proc Nutr Soc 67 (2008) 128-145
40. van Gils C.H., Peeters P.H., Schoenmakers M.C., Nijmeijer R.M., Onland-Moret N.C., van der Schouw Y.T., et al. Physical activity and endogenous sex hormone levels in postmenopausal women: a cross-sectional study in the Prospect-EPIC Cohort. Cancer Epidemiol Biomarkers Prevent 18 (2009) 377-383
41. Monninkhof E.M., Velthuis M.J., Peeters P.H., Twisk J.W., and Schuit A.J. Effect of exercise on postmenopausal sex hormone levels and role of body fat: a randomized controlled trial. J Clin Oncol 27 (2009) 4492-4499
42. Fisher M.B., Vandenbranden M., Findlay K., Burchell B., Thummel K.E., Hall S.D., et al. Tissue distribution and interindividual variation in human UDP-glucuronosyltransferase activity: relationship between UGT1A1 promoter genotype and variability in a liver bank. Pharmacogenetics 10 (2000) 727-739
43. Gall W.E., Zawada G., Mojarrabi B., Tephly T.R., Green M.D., Coffman B.L., et al. Differential glucuronidation of bile acids, androgens and estrogens by human UGT1A3 and 2B7. J Steroid Biochem Mol Biol 70 (1999) 101-108
44. Guillemette C., Belanger A., and Lepine J. Metabolic inactivation of estrogens in breast tissue by UDP-glucuronosyltransferase enzymes: an overview. Breast Cancer Res 6 (2004) 246-254
45. Falany J.L., and Falany C.N. Expression of cytosolic sulfotransferases in normal mammary epithelial cells and breast cancer cell lines. Cancer Res 56 (1996) 1551-1555
46. Lindsay J., Wang L.L., Li Y., and Zhou S.F. Structure, function and polymorphism of human cytosolic sulfotransferases. Curr Drug Metab 9 (2008) 99-105
47. Adjei A.A., and Weinshilboum R.M. Catecholestrogen sulfation: possible role in carcinogenesis. Biochem Biophys Res Commun 292 (2002) 402-408
48. Wang L.Q., and James M.O. Sulfotransferase 2A1 forms estradiol-17-sulfate and celecoxib switches the dominant product from estradiol-3-sulfate to estradiol-17-sulfate. J Steroid Biochem Mol Biol 96 (2005) 367-374
49. Nakata T., Takashima S., Shiotsu Y., Murakata C., Ishida H., Akinaga S., et al. Role of steroid sulfatase in local formation of estrogen in post-menopausal breast cancer patients. J Steroid Biochem Mol Biol 86 (2003) 455-460
50. Tsuchiya Y., Nakajima M., and Yokoi T. Cytochrome P450-mediated metabolism of estrogens and its regulation in human. Cancer Lett 227 (2005) 115-124
51. Delaforge M., Pruvost A., Perrin L., and Andre F. Cytochrome P450-mediated oxidation of glucuronide derivatives: example of estradiol-17beta-glucuronide oxidation to 2-hydroxy-estradiol-17beta-glucuronide by CYP 2C8. Drug Metab Dispos 33 (2005) 466-473
52. Takanashi K., Watanabe K., and Yoshizawa I. Evidence of conversion of estradiol 17-sulfate to its 2- and 4-hydroxylated catechols by human placental microsomes. Biol Pharm Bull 16 (1993) 217-219
53. Dawling S., Roodi N., Mernaugh R.L., Wang X., and Parl F.F. Catechol-O-methyltransferase (COMT)-mediated metabolism of catechol estrogens: comparison of wild-type and variant COMT isoforms. Cancer Res 61 (2001) 6716-6722
54. Hui Y., Yasuda S., Liu M.Y., Wu Y.Y., and Liu M.C. On the sulfation and methylation of catecholestrogens in human mammary epithelial cells and breast cancer cells. Biol Pharm Bull 31 (2008) 769-773
55. Spink B.C., Katz B.H., Hussain M.M., Pang S., Connor S.P., Aldous K.M., et al. SULT1A1 catalyzes 2-methoxyestradiol sulfonation in MCF-7 breast cancer cells. Carcinogenesis 21 (2000) 1947-1957
56. Murray G.I., Melvin W.T., Greenlee W.F., and Burke M.D. Regulation, function, and tissue-specific expression of cytochrome P450 CYP1B1. Annu Rev Pharmacol Toxicol 41 (2001) 297-316
57. Lee A.J., Cai M.X., Thomas P.E., Conney A.H., and Zhu B.T. Characterization of the oxidative metabolites of 17beta-estradiol and estrone formed by 15 selectively expressed human cytochrome p450 isoforms. Endocrinology 144 (2003) 3382-3398
58. Zhao Z., Kosinska W., Khmelnitsky M., Cavalieri E.L., Rogan E.G., Chakravarti D., et al. Mutagenic activity of 4-hydroxyestradiol, but not 2-hydroxyestradiol, in BB rat2 embryonic cells, and the mutational spectrum of 4-hydroxyestradiol. Chem Res Toxicol 19 (2006) 475-479
59. Gao N., Nester R.A., and Sarkar M.A. 4-Hydroxy estradiol but not 2-hydroxy estradiol induces expression of hypoxia-inducible factor 1alpha and vascular endothelial growth factor A through phosphatidylinositol 3-kinase/Akt/FRAP pathway in OVCAR-3 and A2780-CP70 human ovarian carcinoma cells. Toxicol Appl Pharmacol 196 (2004) 124-135
60. Bolton J.L., Trush M.A., Penning T.M., Dryhurst G., and Monks T.J. Role of quinones in toxicology. Chem Res Toxicol 13 (2000) 135-160
61. Bolton J.L., and Thatcher G.R. Potential mechanisms of estrogen quinone carcinogenesis. Chem Res Toxicol 21 (2008) 93-101
62. Blair I.A. Endogenous glutathione adducts. Curr Drug Metab 7 (2006) 853-872
63. Chandrasena R.E., Edirisinghe P.D., Bolton J.L., and Thatcher G.R. Problematic detoxification of estrogen quinones by NAD(P)H-dependent quinone oxidoreductase and glutathione-S-transferase. Chem Res Toxicol 21 (2008) 1324-1329
64. Cheng Z., Rios G.R., King C.D., Coffman B.L., Green M.D., Mojarrabi B., et al. Glucuronidation of catechol estrogens by expressed human UDP-glucuronosyltransferases (UGTs) 1A1, 1A3, and 2B7. Toxicol Sci 45 (1998) 52-57
65. Parl F.F., Egan K.M., Li C., and Crooke P.S. Estrogen exposure, metabolism, and enzyme variants in a model for breast cancer risk prediction. Cancer Inform 7 (2009) 109-121
66. Van Emburgh B.O., Hu J.J., Levine E.A., Mosley L.J., Perrier N.D., Freimanis R.I., et al. Polymorphisms in CYP1B1, GSTM1. GSTT1 and GSTP1, and susceptibility to breast cancer. Oncol Rep 19 (2008) 1311-1321
67. Wen W., Ren Z., Shu X.O., Cai Q., Ye C., Gao Y.T., et al. Expression of cytochrome P450 1B1 and catechol-O-methyltransferase in breast tissue and their associations with breast cancer risk. Cancer Epidemiol Biomarkers Prevent 16 (2007) 917-920
68. Rylander-Rudqvist T., Wedren S., Granath F., Humphreys K., Ahlberg S., Weiderpass E., et al. Cytochrome P450 1B1 gene polymorphisms and postmenopausal breast cancer risk. Carcinogenesis 24 (2003) 1533-1539
69. De Vivo I., Hankinson S.E., Li L., Colditz G.A., and Hunter D.J. Association of CYP1B1 polymorphisms and breast cancer risk. Cancer Epidemiol Biomarkers Prevent 11 (2002) 489-492
70. Zhu B.T., and Conney A.H. Is 2-methoxyestradiol an endogenous estrogen metabolite that inhibits mammary carcinogenesis?. Cancer Res 58 (1998) 2269-2277
71. Lippert T.H., Seeger H., and Mueck A.O. The impact of endogenous estradiol metabolites on carcinogenesis. Steroids 65 (2000) 357-369
72. Mooberry S.L. New insights into 2-methoxyestradiol, a promising antiangiogenic and antitumor agent. Curr Opin Oncol 15 (2003) 425-430
73. Kirches E., and Warich-Kirches M. 2-methoxyestradiol as a potential cytostatic drug in gliomas?. Anticancer Agents Med Chem 9 (2009) 55-65
74. Pasqualini J.R. Estrogen sulfotransferases in breast and endometrial cancers. Ann N Y Acad Sci 1155 (2009) 88-98
75. Gestl S.A., Green M.D., Shearer D.A., Frauenhoffer E., Tephly T.R., and Weisz J. Expression of UGT2B7, a UDP-glucuronosyltransferase implicated in the metabolism of 4-hydroxyestrone and all-trans retinoic acid, in normal human breast parenchyma and in invasive and in situ breast cancers. Am J Pathol 160 (2002) 1467-1479
76. Westerlind K.C., Gibson K.J., Evans G.L., and Turner R.T. The catechol estrogen, 4-hydroxyestrone, has tissue-specific estrogen actions. J Endocrinol 167 (2000) 281-287
77. Newman S.P., Ireson C.R., Tutill H.J., Day J.M., Parsons M.F., Leese M.P., et al. The role of 17beta-hydroxysteroid dehydrogenases in modulating the activity of 2-methoxyestradiol in breast cancer cells. Cancer Res 66 (2006) 324-330
78. Yager J.D., and Davidson N.E. Estrogen carcinogenesis in breast cancer. N Engl J Med 354 (2006) 270-282
79. Huang Z., Guengerich F.P., and Kaminsky L.S. 16Alpha-hydroxylation of estrone by human cytochrome P4503A4/5. Carcinogenesis 19 (1998) 867-872
80. Nebert D.W. Elevated estrogen 16 alpha-hydroxylase activity: is this a genotoxic or nongenotoxic biomarker in human breast cancer risk?. J Natl Cancer Inst 85 (1993) 1888-1891
81. Jernstrom H., Klug T.L., Sepkovic D.W., Bradlow H.L., and Narod S.A. Predictors of the plasma ratio of 2-hydroxyestrone to 16alpha-hydroxyestrone among pre-menopausal, nulliparous women from four ethnic groups. Carcinogenesis 24 (2003) 991-1005
82. Castagnetta L.A., Granata O.M., Traina A., Ravazzolo B., Amoroso M., Miele M., et al. Tissue content of hydroxyestrogens in relation to survival of breast cancer patients. Clin Cancer Res 8 (2002) 3146-3155
83. Telang N.T., Suto A., Wong G.Y., Osborne M.P., and Bradlow H.L. Induction by estrogen metabolite 16 alpha-hydroxyestrone of genotoxic damage and aberrant proliferation in mouse mammary epithelial cells. J Natl Cancer Inst 84 (1992) 634-638
84. Lewis J.S., Thomas T.J., Pestell R.G., Albanese C., Gallo M.A., and Thomas T. Differential effects of 16alpha-hydroxyestrone and 2-methoxyestradiol on cyclin D1 involving the transcription factor ATF-2 in MCF-7 breast cancer cells. J Mol Endocrinol 34 (2005) 91-105
85. Cavalieri E., Frenkel K., Liehr J.G., Rogan E., and Roy D. Estrogens as endogenous genotoxic agents-DNA adducts and mutations. J Natl Cancer Inst Monogr (2000) 75-93
86. Liehr J.G. Role of DNA adducts in hormonal carcinogenesis. Regul Toxicol Pharmacol 32 (2000) 276-282
87. Bradlow H.L., Davis D.L., Lin G., Sepkovic D., and Tiwari R. Effects of pesticides on the ratio of 16 alpha/2-hydroxyestrone: a biologic marker of breast cancer risk. Environ Health Perspect 103 Suppl. 7 (1995) 147-150
88. Im A., Vogel V.G., Ahrendt G., Lloyd S., Ragin C., Garte S., et al. Urinary estrogen metabolites in women at high risk for breast cancer. Carcinogenesis 30 (2009) 1532-1535
89. McShane L.M., Dorgan J.F., Greenhut S., and Damato J.J. Reliability and validity of serum sex hormone measurements. Cancer Epidemiol Biomarkers Prevent 5 (1996) 923-928
90. Stanczyk F.Z., Cho M.M., Endres D.B., Morrison J.L., Patel S., and Paulson R.J. Limitations of direct estradiol and testosterone immunoassay kits. Steroids 68 (2003) 1173-1178
91. Bansal S., and DeStefano A. Key elements of bioanalytical method validation for small molecules. AAPS J 9 (2007) E109-E114
92. Kushnir M.M., Rockwood A.L., Bergquist J., Varshavsky M., Roberts W.L., Yue B., et al. High-sensitivity tandem mass spectrometry assay for serum estrone and estradiol. Am J Clin Pathol 129 (2008) 530-539
93. Longcope C., Hui S.L., and Johnston Jr. C.C. Free estradiol, free testosterone, and sex hormone-binding globulin in perimenopausal women. J Clin Endocrinol Metab 64 (1987) 513-518
94. Rinaldi S., Geay A., Dechaud H., Biessy C., Zeleniuch-Jacquotte A., Akhmedkhanov A., et al. Validity of free testosterone and free estradiol determinations in serum samples from postmenopausal women by theoretical calculations. Cancer Epidemiol Biomarkers Prevent 11 (2002) 1065-1071
95. Endogenous Hormones and Breast Cancer Collaborative Group. Free estradiol and breast cancer risk in postmenopausal women: comparison of measured and calculated values. Cancer Epidemiol Biomarkers Prevent 12 (2003) 1457-1461
96. Hobe G., Schon R., Goncharov N., Katsiya G., Koryakin M., Gesson-Cholat I., et al. Some new aspects of 17alpha-estradiol metabolism in man. Steroids 67 (2002) 883-893
97. Santen R.J., Lee J.S., Wang S., Demers L.M., Mauras N., Wang H., et al. Potential role of ultra-sensitive estradiol assays in estimating the risk of breast cancer and fractures. Steroids 73 (2008) 1318-1321
98. Santen R.J., Demers L., Ohorodnik S., Settlage J., Langecker P., Blanchett D., et al. Superiority of gas chromatography/tandem mass spectrometry assay (GC/MS/MS) for estradiol for monitoring of aromatase inhibitor therapy. Steroids 72 (2007) 666-671
99. Rinaldi S., Dechaud H., Toniolo P., and Kaaks R. Reliability and validity of direct radioimmunoassays for measurement of postmenopausal serum androgens and estrogens. IARC Sci Publ 156 (2002) 323-325
100. Lee J.S., Ettinger B., Stanczyk F.Z., Vittinghoff E., Hanes V., Cauley J.A., et al. Comparison of methods to measure low serum estradiol levels in postmenopausal women. J Clin Endocrinol Metab 91 (2006) 3791-3797
101. Hsing A.W., Stanczyk F.Z., Belanger A., Schroeder P., Chang L., Falk R.T., et al. Reproducibility of serum sex steroid assays in men by RIA and mass spectrometry. Cancer Epidemiol Biomarkers Prevent 16 (2007) 1004-1008
102. Stanway S.J., Purohit A., and Reed M.J. Measurement of estrone sulfate in postmenopausal women: comparison of direct RIA and GC-MS/MS methods for monitoring response to endocrine therapy in women with breast cancer. Anticancer Res 27 (2007) 2765-2767
103. Geisler J., Ekse D., Helle H., Duong N.K., and Lonning P.E. An optimised, highly sensitive radioimmunoassay for the simultaneous measurement of estrone, estradiol and estrone sulfate in the ultra-low range in human plasma samples. J Steroid Biochem Mol Biol 109 (2008) 90-95
104. Cao Z., Swift T.A., West C.A., Rosano T.G., and Rej R. Immunoassay of estradiol: unanticipated suppression by unconjugated estriol. Clin Chem 50 (2004) 160-165
105. Geisler J., Helle H., Ekse D., Duong N.K., Evans D.B., Nordbo Y., et al. Letrozole is superior to anastrozole in suppressing breast cancer tissue and plasma estrogen levels. Clin Cancer Res 14 (2008) 6330-6335
106. Lonning P.E., and Geisler J. Evaluation of plasma and tissue estrogen suppression with third generation aromatase inhibitors: of relevance to clinical understanding?. J Steroid Biochem Mol Biol (2009) doi:10.1016/j.jsbmb.2009.09.013
107. Toniolo P., and Lukanova A. The challenge of measuring circulating estradiol at low concentrations. Breast Cancer Res 7 (2005) 45-47
108. Oe T., Ackermann B.L., Inoue K., Berna M.J., Garner C.O., Gelfanova V., et al. Quantitative analysis of amyloid beta peptides in cerebrospinal fluid of Alzheimer's disease patients by immunoaffinity purification and stable isotope dilution liquid chromatography/negative electrospray ionization tandem mass spectrometry. Rapid Commun Mass Spectrom 20 (2006) 3723-3735
109. Ceglarek U., Kortz L., Leichtle A., Fiedler G.M., Kratzsch J., and Thiery J. Rapid quantification of steroid patterns in human serum by on-line solid phase extraction combined with liquid chromatography-triple quadrupole linear ion trap mass spectrometry. Clin Chim Acta 401 (2009) 114-118
110. Hosogi J., Tanaka H., Fujita K., Kuwabara T., Ikegawa S., Kobayashi N., et al. LC-MS/MS coupled with immunoaffinity extraction for determination of estrone, 17beta-estradiol and estrone 3-sulfate in human plasma. J Chromatogr B Analyt Technol Biomed Life Sci 878 (2010) 222-227
111. Tai S.S., and Welch M.J. Development and evaluation of a reference measurement procedure for the determination of estradiol-17beta in human serum using isotope-dilution liquid chromatography-tandem mass spectrometry. Anal Chem 77 (2005) 6359-6363
112. Singh G., Gutierrez A., Xu K., and Blair I.A. Liquid chromatography/electron capture atmospheric pressure chemical ionization/mass spectrometry: analysis of pentafluorobenzyl derivatives of biomolecules and drugs in the attomole range. Anal Chem 72 (2000) 3007-3013
113. Higashi T., Takayama N., Nishio T., Taniguchi E., and Shimada K. Procedure for increasing the detection responses of estrogens in LC-MS based on introduction of a nitrobenzene moiety followed by electron capture atmospheric pressure chemical ionization. Anal Bioanal Chem 386 (2006) 658-665
114. Penning TM, Lee SH, Jin Y, Gutierrez A, Blair IA. Liquid-chromatography mass spectrometry (LC-MS) of steroid hormone metabolites and its applications. J Steroid Biochem Mol Biol 2010, doi:10.1016/j.jsbmb.2010.01.005.
115. Xu X., Roman J.M., Issaq H.J., Keefer L.K., Veenstra T.D., and Ziegler R.G. Quantitative measurement of endogenous estrogens and estrogen metabolites in human serum by liquid chromatography-tandem mass spectrometry. Anal Chem 79 (2007) 7813-7821
116. Yamashita K., Okuyama M., Watanabe Y., Honma S., Kobayashi S., and Numazawa M. Highly sensitive determination of estrone and estradiol in human serum by liquid chromatography-electrospray ionization tandem mass spectrometry. Steroids 72 (2007) 819-827
117. Xu L., and Spink D.C. Analysis of steroidal estrogens as pyridine-3-sulfonyl derivatives by liquid chromatography electrospray tandem mass spectrometry. Anal Biochem 375 (2008) 105-114
118. Lin Y.H., Chen C.Y., and Wang G.S. Analysis of steroid estrogens in water using liquid chromatography/tandem mass spectrometry with chemical derivatizations. Rapid Commun Mass Spectrom 21 (2007) 1973-1983
119. Nishio T., Higashi T., Funaishi A., Tanaka J., and Shimada K. Development and application of electrospray-active derivatization reagents for hydroxysteroids. J Pharm Biomed Anal 44 (2007) 786-795
120. Yang W.C., Regnier F.E., Sliva D., and Adamec J. Stable isotope-coded quaternization for comparative quantification of estrogen metabolites by high-performance liquid chromatography-electrospray ionization mass spectrometry. J Chromatogr B: Anal Technol Biomed Life Sci 870 (2008) 233-240
121. Griffiths W.J., Liu S., Alvelius G., and Sjovall J. Derivatisation for the characterisation of neutral oxosteroids by electrospray and matrix-assisted laser desorption/ionisation tandem mass spectrometry: the Girard P derivative. Rapid Commun Mass Spectrom 17 (2003) 924-935
122. Johnson D.W. Ketosteroid profiling using Girard T derivatives and electrospray ionization tandem mass spectrometry: direct plasma analysis of androstenedione, 17-hydroxyprogesterone and cortisol. Rapid Commun Mass Spectrom 19 (2005) 193-200
123. Joubert A., Van Z.H., Laurens J., and Lottering M.L. C2- and C4-position 17beta-estradiol metabolites and their relation to breast cancer. Biocell 33 (2009) 137-140